Part D Plans Would Need To Cover COVID-19 Drugs Without Cost Sharing Under House Bill
US House leadership's COVID-19 aid package focuses on cost sharing relief for patients to ensure access to treatments and vaccines for the virus. The Senate's legislative proposal tried to provide Medicare reimbursement incentives to providers to facilitate uptake, but some of those provisions were later dropped.
You may also be interested in...
Payer concessions to ensure access to drugs during the COVID-19 outbreak offer a benefit to patients and biopharma. But the costs involved could intensify future efforts to manage drug spending.
Early versions of US Congress's coronavirus relief bill contained a number of policies that would have benefited drug firms, but they didn't make it into the final bill. However, the $2 trillion package does provide pharmaceutical companies with relief from the threat of drug pricing reform until after the 2020 elections.
Provisions adapted from DISARM Act would carve out antimicrobials from hospital bundled payments and allow reimbursement equal to 100% of a drug’s average sales price.